NCT06520410 Safety and Efficacy of 18 mm Short Vitrectomy Probe for Pediatric Vitreoretinal Surgeries
| NCT ID | NCT06520410 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Chang Gung Memorial Hospital |
| Condition | Retinopathy of Prematurity Both Eyes |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-03-05 |
| Primary Completion | 2026-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 60 participants in total. It began in 2024-03-05 with a primary completion date of 2026-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to study the safety and efficacy of using an 18 mm short vitrectomy probe for pediatric vitreoretinal surgeries and to investigate the surgeon's comfort and reliability of using the shorter probe.
Eligibility Criteria
Inclusion Criteria: * Patients less than 18 years old * Need vitrectomy due to various etiologies, including retinopathy of prematurity, familial exudative vitreoretinopathy, persistent fetal vasculature, congenital cataract, lens dislocation, open-globe injury, vitreous hemorrhage, or other vitreoretinal diseases. Exclusion Criteria: * Patients who cannot cooperate fully with detailed ophthalmic examinations.
Contact & Investigator
Wei-Chi Wu, MD, PhD
STUDY CHAIR
Chang Gung Medical Foundation
Frequently Asked Questions
Who can join the NCT06520410 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 18 Years, studying Retinopathy of Prematurity Both Eyes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06520410 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06520410 currently recruiting?
Yes, NCT06520410 is actively recruiting participants. Contact the research team at weichi666@gmail.com for enrollment information.
Where is the NCT06520410 trial being conducted?
This trial is being conducted at Taoyuan, Taiwan.
Who is sponsoring the NCT06520410 clinical trial?
NCT06520410 is sponsored by Chang Gung Memorial Hospital. The principal investigator is Wei-Chi Wu, MD, PhD at Chang Gung Medical Foundation. The trial plans to enroll 60 participants.